Author
Listed:
- Michael Holmes
- Christopher Carroll
- Diana Papaioannou
Abstract
The National Institute for Health and Clinical Excellence (NICE) invited Boehringer Ingelheim GmbH, the manufacturer of dabigatran etexilate (DBG), to submit evidence on the clinical and cost effectiveness of this drug for the primary prevention of venous thromboembolism (VTE) in adult patients who have undergone total hip replacement (THR) or total knee replacement (TKR) surgery, as part of NICE’s single technology appraisal process. The comparators were enoxaparin and fondaparinux, as identified in the scope issued by NICE. The School of Health and Related Research at the University of Sheffield was commissioned to act as the Evidence Review Group (ERG). This article provides a description of the company submission, the ERG review and NICE’s subsequent decisions. Clinical-effectiveness evidence for DBG versus enoxaparin was derived from two randomized, double-blind, noninferiority trials, one for THR and the other for TKR. Clinical-effectiveness evidence for DBG versus fondaparinux was taken from a mixed treatment comparison (MTC) and from one study. The results presented show that DBG at the licensed dose of 220mg and 150mg once daily was noninferior to enoxaparin (40mg once daily) in terms of the primary efficacy outcome of total VTE and all-cause mortality. In the MTC, fondaparinux was found to be more effective than DBG; the level of statistical significance was not reported. The manufacturer’s cost-effectiveness model estimated that at a dose of 220mg once a day, DBG dominated enoxaparin in both THR and TKR. At a dose of 150mg daily, DBG dominated enoxaparin in THR, while enoxaparin dominated DBG in TKR. At a dose of 220mg daily, DBG was less cost effective than fondaparinux in THR. The cost per QALY gained for fondaparinux versus DBG was £11111 (year 2008 values). At a dose of 150mg daily, DBG was less cost effective than fondaparinux in THR. The cost per QALY gained for fondaparinux versus DBG was £6857 (year 2008 values). In TKR, both DBG doses were dominated by fondaparinux. There was some evidence that DBG was more cost effective than enoxaparin; however, these results were based on only one trial each in THR and TKR. Fondaparinux appeared to be more cost effective than DBG; however, this was based on indirect comparisons. NICE concluded that although there was uncertainty in the evidence base, DBG was very likely to be of equivalent clinical and cost effectiveness to enoxaparin or fondaparinux in the prevention of VTE. The NICE Appraisal Committee (AC) acknowledged that oral administration of DBG, without the need for monitoring, would reduce administration costs and that it may support adherence to treatment. Therefore, the AC concluded that DBG should be recommended as an option in the circumstances in which enoxaparin (or fondaparinux as an alternative) may be offered. Copyright Springer International Publishing AG 2012
Suggested Citation
Michael Holmes & Christopher Carroll & Diana Papaioannou, 2012.
"Dabigatran Etexilate for the Prevention of Venous Thromboembolism in Patients Undergoing Elective Hip or Knee Surgery,"
PharmacoEconomics, Springer, vol. 30(2), pages 137-146, February.
Handle:
RePEc:spr:pharme:v:30:y:2012:i:2:p:137-146
DOI: 10.2165/11591590-000000000-00000
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
Citations
Citations are extracted by the
CitEc Project, subscribe to its
RSS feed for this item.
Cited by:
- Jane Burch & Susan Griffin & Claire McKenna & Simon Walker & James Paton & Kath Wright & Nerys Woolacott, 2012.
"Omalizumab for the Treatment of Severe Persistent Allergic Asthma in Children Aged 6–11 Years,"
PharmacoEconomics, Springer, vol. 30(11), pages 991-1004, November.
- Sophie Whyte & Abdullah Pandor & Matt Stevenson, 2012.
"Bevacizumab for Metastatic Colorectal Cancer,"
PharmacoEconomics, Springer, vol. 30(12), pages 1119-1132, December.
- Dwayne Boyers & Xueli Jia & David Jenkinson & Graham Mowatt, 2012.
"Eltrombopag for the Treatment of Chronic Immune or Idiopathic Thrombocytopenic Purpura,"
PharmacoEconomics, Springer, vol. 30(6), pages 483-495, June.
- Sophie Whyte & Abdullah Pandor & Matt Stevenson, 2012.
"Bevacizumab for Metastatic Colorectal Cancer,"
PharmacoEconomics, Springer, vol. 30(12), pages 1119-1132, December.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:30:y:2012:i:2:p:137-146. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.